These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20624663)

  • 1. [Added value of prone position technique for PET-TAC in breast cancer patients].
    Vidal-Sicart S; Aukema TS; Vogel WV; Hoefnagel CA; Valdés-Olmos RA
    Rev Esp Med Nucl; 2010; 29(5):230-5. PubMed ID: 20624663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.
    Teixeira SC; Koolen BB; Vogel WV; Wesseling J; Stokkel MP; Vrancken Peeters MJ; van der Noort V; Rutgers EJ; Valdés Olmos RA
    Clin Nucl Med; 2016 Apr; 41(4):e181-6. PubMed ID: 26704731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position.
    Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH
    Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prone 18F-FDG PET/CT changes diagnostic and surgical intervention in a breast cancer patient: some considerations about PET/CT imaging acquisition protocol.
    Canevari C; Gallivanone F; Zuber V; Marassi A; Losio C; Gianolli L; Gilardi MC; Castiglioni I
    Clin Imaging; 2015; 39(3):506-9. PubMed ID: 25620014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First clinical experience with a dedicated PET for hanging breast molecular imaging.
    Koolen BB; Aukema TS; González Martínez AJ; Vogel WV; Caballero Ontanaya L; Vrancken Peeters MJ; Vroonland CJ; Rutgers EJ; Benlloch Baviera JM; Valdés Olmos RA
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):92-100. PubMed ID: 23474637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved breast cancer detection of prone breast fluorodeoxyglucose-PET in 118 patients.
    Kaida H; Ishibashi M; Fuji T; Kurata S; Uchida M; Baba K; Miyagawa T; Kaibara H; Kawamura S; Ogo E; Hayabuchi N
    Nucl Med Commun; 2008 Oct; 29(10):885-93. PubMed ID: 18769306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using (18)F-FLT PET to distinguish between malignant and benign breast lesions with suspicious findings in mammography and breast ultrasound.
    Wang J; Kuo WH; Shih TT; Yen RF
    Ann Nucl Med; 2014 Dec; 28(10):941-9. PubMed ID: 25139471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of preoperative investigation with 18-FDG-PET/CT in primary operable breast cancer].
    Garami Z; Hascsi Z; Garai I; Tanyi M; Lukács G; Damjanovich L
    Magy Seb; 2009 Jun; 62(3):107-12. PubMed ID: 19525175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
    Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
    Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    van Loevezijn AA; Stokkel MPM; Donswijk ML; van Werkhoven ED; van der Noordaa MEM; van Duijnhoven FH; Vrancken Peeters MTFD
    EJNMMI Res; 2021 Aug; 11(1):78. PubMed ID: 34417932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
    Estrada-Sánchez G; Ochoa-Carrillo FJ; Altamirano-Ley J
    Cir Cir; 2008; 76(4):279-86. PubMed ID: 18778536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans.
    Moy L; Noz ME; Maguire GQ; Ponzo F; Deans AE; Murphy-Walcott AD; Kramer EL
    Clin Nucl Med; 2007 Mar; 32(3):194-8. PubMed ID: 17314593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.